An increased prevalence of proliferative retinopathy is also observed in patients with acromegaly.98 Whether GHR-targeted strategies will be an effective treatment for retinopathy is still a matter of debate: a small clinical study using the GHR antagonist, pegvisomant, did not observe regression of proliferative diabetic retinopathy. The gene discussed is GHR; the disease is retinal disorder.